Osiris Therapeutics, Inc. (OSIR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.80 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
Osiris Therapeutics To Present At The 9th Annual JMP Securities Healthcare Conference

Osiris Therapeutics To Present At The 9th Annual JMP Securities Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets, announced today that Lode Debrabandere, ...

Grafix® Manuscript From Osiris’ Multi-center, Randomized, Controlled Clinical Trial Accepted In Peer-Reviewed Journal

Grafix® Manuscript From Osiris’ Multi-center, Randomized, Controlled Clinical Trial Accepted In Peer-Reviewed Journal

Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to control in ...

Osiris Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference

Osiris Therapeutics To Present At The Jefferies 2014 Global Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets, announced today that Lode Debrabandere, ...

3 Stocks Spiking on Unusual Volume

3 Stocks Spiking on Unusual Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Osiris Reports First Quarter 2014 Results: Revenue Up 25% And Gross Margin Improved From 73% To 78%

Osiris Reports First Quarter 2014 Results: Revenue Up 25% And Gross Margin Improved From 73% To 78%

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for ...

Synthes Chairman Emeritus Hansjörg Wyss Joins Osiris As A Strategic Advisor

Synthes Chairman Emeritus Hansjörg Wyss Joins Osiris As A Strategic Advisor

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets, announced today that Hansjörg Wyss will...

Osiris Therapeutics Announces First Quarter 2014 Financial Results Conference Call

Osiris Therapeutics Announces First Quarter 2014 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for first quarter ended March 31, 2014, on Tuesday, May 13, 2014.

Osiris Therapeutics Announces Dwayne Montgomery As General Manager Of Orthopedics And Sports Medicine

Osiris Therapeutics Announces Dwayne Montgomery As General Manager Of Orthopedics And Sports Medicine

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, is pleased to ...

Grafix® Pharmacoeconomic And Scientific Characterization Studies Featured At The 2014 Spring Symposium For Advanced Wound Care

Grafix® Pharmacoeconomic And Scientific Characterization Studies Featured At The 2014 Spring Symposium For Advanced Wound Care

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that results from both a pharmacoeconomic evaluation and a scientific characterization (cryopreservation versus non-cryopreservation) of Grafix® will be ...

Osiris Announces Receipt Of $15 Million Cash Payment For Prochymal

Osiris Announces Receipt Of $15 Million Cash Payment For Prochymal

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it ...

3 Big-Volume Stocks in Breakout Territory

3 Big-Volume Stocks in Breakout Territory

These stocks rising on unusual volume are within range of triggering breakout trades.

Osiris Therapeutics Announces Therésa K. Dixon As General Manager Of Market Access And Reimbursement

Osiris Therapeutics Announces Therésa K. Dixon As General Manager Of Market Access And Reimbursement

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, is pleased to ...

Osiris Therapeutics To Present At The 2nd Annual Regen Med Investor Day

Osiris Therapeutics To Present At The 2nd Annual Regen Med Investor Day

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that ...

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) has been downgraded by TheStreet Ratings from from a hold to sell.

Osiris Therapeutics Reports Change In Tax Benefit Allocation For Fourth Quarter And Full Year 2013 Financial Results

Osiris Therapeutics Reports Change In Tax Benefit Allocation For Fourth Quarter And Full Year 2013 Financial Results

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today an accounting adjustment to its Fourth Quarter and Full Year 2013 financial results reported on March 5.

Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference

Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that ...

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) has been downgraded by TheStreet Ratings from from a hold to sell.

Ratings Changes Today

Upgrades: AMCN, CCK, ERF, ERII, ZIGO Downgrades: CWST, DWSN, EGO, OSIR, PLPC, POZN, SATS Initiations: TU Read on to get TheStreet Quant Ratings' detailed report:

Osiris Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results: For The Full Year, Revenue Increased 3-Fold, Company Was Profitable And Ended With Assets Of $92.0 Million

Osiris Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results: For The Full Year, Revenue Increased 3-Fold, Company Was Profitable And Ended With Assets Of $92.0 Million

Osiris Therapeutics, Inc. (NASDAQ:OSIR) the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced today its ...

Cartiform® Featured In Presentation At The 2014 American Academy Of Orthopaedic Surgeons Annual Meeting

Cartiform® Featured In Presentation At The 2014 American Academy Of Orthopaedic Surgeons Annual Meeting

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that a scientific study evaluating the key attributes of Cartiform® will be presented at the 2014 American Academy of Orthopaedic Surgeons (AAOS) Annual...

Osiris Therapeutics Promotes Frank Czworka To Vice President And General Manager Of Wound Care

Osiris Therapeutics Promotes Frank Czworka To Vice President And General Manager Of Wound Care

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets is pleased to ...

Osiris Therapeutics Announces Fourth Quarter And Full Year 2013 Financial Results Conference Call

Osiris Therapeutics Announces Fourth Quarter And Full Year 2013 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2013, on Wednesday, March 5, 2014.

Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, As President And Chief Executive Officer

Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, As President And Chief Executive Officer

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets is pleased to ...

Osiris Announces Receipt Of $15 Million Milestone Payment For Prochymal

Osiris Announces Receipt Of $15 Million Milestone Payment For Prochymal

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in orthopedic, sports medicine and wound care markets announced that it has ...

Journal Publishes Grafix® Clinical Study For Chronic Wounds

Journal Publishes Grafix® Clinical Study For Chronic Wounds

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that data, published in Ostomy ...

Osiris Therapeutics Inc. Stock Upgraded (OSIR)

Osiris Therapeutics Inc. Stock Upgraded (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) has been upgraded by TheStreet Ratings from a sell to hold.

Ratings Changes Today

Upgrades: ASUR, BRK.A, CIM, OINK, OSIR, PCTI, WILC Downgrades: CNTY, EMAN, FRD, HPT, PCG, PLPM, SP Z Initiations: AIRI, DKL, RH, SXE Read on to get TheStreet Quant Ratings' detailed report:

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in orthopedic, sports medicine and wound care markets announced today C.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Osiris Provides Update On Proposed Ruling By CMS

Osiris Provides Update On Proposed Ruling By CMS

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that, on November 27, 2013, the ...